Skip to main content
Top
Published in: BMC Musculoskeletal Disorders 1/2015

Open Access 01-12-2015 | Research article

Patient-centered psoriatic arthritis (PsA) activity assessment by Stockerau Activity Score for Psoriatic Arthritis (SASPA)

Authors: Burkhard F Leeb, Pia M Haindl, Hans-Peter Brezinschek, Harsono T H Mai, Christoph Deutsch, Bernhard Rintelen

Published in: BMC Musculoskeletal Disorders | Issue 1/2015

Login to get access

Abstract

Background

To investigate whether a modified Rheumatoid Arthritis Disease Activity Index-5 could be applied as a routine assessment tool for psoriatic arthritis (PsA) patients.

Methods

Ninety-seven PsA outpatients (mean age 49.78 years; age range 23–80 years; 49 male, 48 female), completed a prototype questionnaire. Tender and swollen joint counts, including enthesiopathy, physician’s assessment of disease activity on a visual analog scale (MDglob), erythrocyte sedimentation rate, and patient satisfaction with disease status (PatSat: 1 = excellent to 5 = unsatisfactory) were recorded. Factorial analysis was performed and alpha, as a measure of reliability, and tau were calculated. The ultimate five-item questionnaire, calculated by (Q1 + Q2 + Q3 + Q4 + Q5)/5, was then handed over to 152 PsA outpatients (mean age 54.02 years; age range 26–80 years; 82 male, 70 female), and analyzed accordingly.

Results

Analyzing the internal consistency of the prototype questionnaire revealed the highest alpha value of 0.849, on deleting the question targeting disease course. Alpha for the final Stockerau Activity Score for Psoriatic Arthritis (SASPA) was 0.875, with all items contributing to the final result (item loading from 0.573 to 0.910). Kendall’s tau for the relationship between SASPA scores and swollen joint count, tender joint count, and MDglob was 0.34, 0.416, and 0.392, respectively. The sensitivity of the questionnaire to change was demonstrated in patients starting treatment with a tumor necrosis factor blocker (standardized mean difference: 2.1).

Conclusion

The SASPA questionnaire constitutes a fully patient-administered tool to monitor PsA activity. Its reliability, convergent validity, and sensitivity to change were demonstrated.
Literature
1.
go back to reference Leeb BF, Smolen JS. Arthritis psoriatica. In: Ganten D, Ruckpaul K, editors. Molekularmedizinische Grundlagen von rheumatischen erkrankungen. Berlin Heidelberg: Springer-Verlag; 2003. p. 377–86.CrossRef Leeb BF, Smolen JS. Arthritis psoriatica. In: Ganten D, Ruckpaul K, editors. Molekularmedizinische Grundlagen von rheumatischen erkrankungen. Berlin Heidelberg: Springer-Verlag; 2003. p. 377–86.CrossRef
2.
go back to reference Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol. 2001;28:1842–6.PubMed Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol. 2001;28:1842–6.PubMed
3.
go back to reference Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, et al. European league against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71:4–12.CrossRefPubMed Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, et al. European league against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71:4–12.CrossRefPubMed
4.
go back to reference Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69:48–53.CrossRefPubMed Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69:48–53.CrossRefPubMed
5.
go back to reference Smolen JS, Braun J, Dougados M, Emery P, Fitzgerald O, Helliwell P, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73:6–16.CrossRefPubMed Smolen JS, Braun J, Dougados M, Emery P, Fitzgerald O, Helliwell P, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73:6–16.CrossRefPubMed
6.
go back to reference Coates LC, Navarro-Coy N, Brown SR, Brown S, McParland L, Collier H, et al. The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskelet Disord. 2013;14:101.CrossRefPubMedPubMedCentral Coates LC, Navarro-Coy N, Brown SR, Brown S, McParland L, Collier H, et al. The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskelet Disord. 2013;14:101.CrossRefPubMedPubMedCentral
7.
go back to reference Salaffi F, Ciapetti A, Carotti M, Gasparini S, Gutierrez M. Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world. Biomed Res Int. 2014;2014:528105.CrossRefPubMedPubMedCentral Salaffi F, Ciapetti A, Carotti M, Gasparini S, Gutierrez M. Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world. Biomed Res Int. 2014;2014:528105.CrossRefPubMedPubMedCentral
8.
go back to reference Prevoo ML, Van’t Hof MA, Kuper HH, Van Leeuwen MA, van de Putte LB, Van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.CrossRefPubMed Prevoo ML, Van’t Hof MA, Kuper HH, Van Leeuwen MA, van de Putte LB, Van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.CrossRefPubMed
9.
go back to reference Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of disease activity score (DAS)28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis. 2007;66:407–9.CrossRefPubMed Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of disease activity score (DAS)28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis. 2007;66:407–9.CrossRefPubMed
10.
go back to reference Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;42:244–57.CrossRef Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;42:244–57.CrossRef
11.
go back to reference Helliwell PS, FitzGerald O, Fransen J. Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response. J Rheumatol. 2014;41:1212–7.CrossRefPubMed Helliwell PS, FitzGerald O, Fransen J. Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response. J Rheumatol. 2014;41:1212–7.CrossRefPubMed
12.
go back to reference Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res. 2011;63:S64–85.CrossRef Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res. 2011;63:S64–85.CrossRef
13.
go back to reference Van Riel PL. The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28). Clin Exp Rheumatol. 2014;32(5 Suppl 85):S65–74. Van Riel PL. The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28). Clin Exp Rheumatol. 2014;32(5 Suppl 85):S65–74.
14.
go back to reference Leeb BF, Andel I, Sautner J, Fassl C, Nothnagl T, Rintelen B. The DAS28 in rheumatoid arthritis and psoriatic arthritis patients. Arthritis Rheum. 2007;57:256–60.CrossRefPubMed Leeb BF, Andel I, Sautner J, Fassl C, Nothnagl T, Rintelen B. The DAS28 in rheumatoid arthritis and psoriatic arthritis patients. Arthritis Rheum. 2007;57:256–60.CrossRefPubMed
15.
go back to reference Mease PJ, Antoni CE, Gladman DD, Taylor WJ. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis. 2005;64 Suppl 2:49–54. Mease PJ, Antoni CE, Gladman DD, Taylor WJ. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis. 2005;64 Suppl 2:49–54.
16.
go back to reference Helliwell PS, Kavanaugh A. Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab. Arthritis Care Res (Hoboken). 2014;66:749–56.CrossRef Helliwell PS, Kavanaugh A. Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab. Arthritis Care Res (Hoboken). 2014;66:749–56.CrossRef
17.
go back to reference Pincus T, Amara I, Segurado OG, Bergman M, Koch GG. Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. J Rheumatol. 2008;35:201–5.CrossRefPubMed Pincus T, Amara I, Segurado OG, Bergman M, Koch GG. Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. J Rheumatol. 2008;35:201–5.CrossRefPubMed
18.
go back to reference Pincus T, Strand V, Koch G, Amara I, Crawford B, Wolfe F, et al. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial. Arthritis Rheum. 2003;48:625–30.CrossRefPubMed Pincus T, Strand V, Koch G, Amara I, Crawford B, Wolfe F, et al. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial. Arthritis Rheum. 2003;48:625–30.CrossRefPubMed
19.
go back to reference Pincus T, Bergman MJ, Yazici Y, Hines P, Raghupathi K, Maclean R. An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. Rheumatology (Oxford). 2008;47:345–9.CrossRef Pincus T, Bergman MJ, Yazici Y, Hines P, Raghupathi K, Maclean R. An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. Rheumatology (Oxford). 2008;47:345–9.CrossRef
20.
go back to reference Leeb BF, Haindl PM, Maktari A, Nothnagl T, Rintelen B. Patient-centered rheumatoid arthritis disease activity assessment by a modified RADAI. J Rheumatol. 2008;35:1294–9.PubMed Leeb BF, Haindl PM, Maktari A, Nothnagl T, Rintelen B. Patient-centered rheumatoid arthritis disease activity assessment by a modified RADAI. J Rheumatol. 2008;35:1294–9.PubMed
21.
go back to reference Leeb BF, Sautner J, Mai HTH, Haindl PM, Deutsch C, Rintelen B. A comparison of patient questionnaires and composite indexes in routine care of rheumatoid arthritis patients. Joint Bone Spine. 2009;76:658–64.CrossRefPubMed Leeb BF, Sautner J, Mai HTH, Haindl PM, Deutsch C, Rintelen B. A comparison of patient questionnaires and composite indexes in routine care of rheumatoid arthritis patients. Joint Bone Spine. 2009;76:658–64.CrossRefPubMed
22.
go back to reference Leeb BF, Haindl PM, Brezinschek HP, Nothnagl T, Rintelen B. RADAI-5 to monitor rheumatoid arthritis. Clin Exp Rheumatol. 2014;32(5 Suppl 85):S55–8. Leeb BF, Haindl PM, Brezinschek HP, Nothnagl T, Rintelen B. RADAI-5 to monitor rheumatoid arthritis. Clin Exp Rheumatol. 2014;32(5 Suppl 85):S55–8.
23.
go back to reference Palominos PE, Gaujoux-Viala C, Fautrel B, Dougados M, Gossec L. Clinical outcomes in psoriatic arthritis: a systematic literature review. Arthritis Care Res. 2012;64:397–406.CrossRef Palominos PE, Gaujoux-Viala C, Fautrel B, Dougados M, Gossec L. Clinical outcomes in psoriatic arthritis: a systematic literature review. Arthritis Care Res. 2012;64:397–406.CrossRef
24.
go back to reference Gladman DD, Mease PJ, Strand V, Healy P, Helliwell PS, Fitzgerald O, et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol. 2007;34:1167–70.PubMed Gladman DD, Mease PJ, Strand V, Healy P, Helliwell PS, Fitzgerald O, et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol. 2007;34:1167–70.PubMed
25.
go back to reference Leeb BF, Andel I, Leder S, Leeb BA, Rintelen B. The patient’s perspective and disease activity indexes. Rheumatology (Oxford). 2005;44:360–5.CrossRef Leeb BF, Andel I, Leder S, Leeb BA, Rintelen B. The patient’s perspective and disease activity indexes. Rheumatology (Oxford). 2005;44:360–5.CrossRef
26.
go back to reference Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297–334.CrossRef Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297–334.CrossRef
28.
go back to reference Abdi H. Kendall rank correlation. In: Salkind NJ, editor. Encyclopedia of measurement and statistics. Thousand Oaks: Sage; 2007. Abdi H. Kendall rank correlation. In: Salkind NJ, editor. Encyclopedia of measurement and statistics. Thousand Oaks: Sage; 2007.
29.
go back to reference Leeb BF, Böttcher E, Brezinschek HP, Czerwenka C, Herold M, Hitzelhammer H, et al. The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project. Clin Rheumatol. 2010;29:167–74.CrossRefPubMed Leeb BF, Böttcher E, Brezinschek HP, Czerwenka C, Herold M, Hitzelhammer H, et al. The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project. Clin Rheumatol. 2010;29:167–74.CrossRefPubMed
31.
go back to reference Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851–64.CrossRefPubMed Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851–64.CrossRefPubMed
32.
go back to reference Qureshi AA, Husni ME, Mody E. Psoriatic arthritis and psoriasis: need for a multidisciplinary approach. Semin Cutan Med Surg. 2005;24:46–51.CrossRefPubMed Qureshi AA, Husni ME, Mody E. Psoriatic arthritis and psoriasis: need for a multidisciplinary approach. Semin Cutan Med Surg. 2005;24:46–51.CrossRefPubMed
33.
go back to reference Coates LC, FitzGerald O, Gladman DD, McHugh N, Mease P, Strand V, et al. Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease. Arthritis Rheum. 2013;65:1504–9.CrossRefPubMed Coates LC, FitzGerald O, Gladman DD, McHugh N, Mease P, Strand V, et al. Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease. Arthritis Rheum. 2013;65:1504–9.CrossRefPubMed
34.
go back to reference Pincus T. A multidimensional health assessment questionnaire (MDHAQ) for all patients with rheumatic diseases to complete at all visits in standard clinical care. Bull NYH Hosp Jt Dis. 2007;65:150–60. Pincus T. A multidimensional health assessment questionnaire (MDHAQ) for all patients with rheumatic diseases to complete at all visits in standard clinical care. Bull NYH Hosp Jt Dis. 2007;65:150–60.
35.
go back to reference Pincus T. Pain, function, and RAPID scores: vital signs in chronic diseases analogous to pulse and temperature in acute diseases and blood pressure and cholesterol in long-term health. Bull NYU Hosp Jt Dis. 2008;66:155–65.PubMed Pincus T. Pain, function, and RAPID scores: vital signs in chronic diseases analogous to pulse and temperature in acute diseases and blood pressure and cholesterol in long-term health. Bull NYU Hosp Jt Dis. 2008;66:155–65.PubMed
36.
go back to reference Zatarain E, Strand V. Monitoring disease activity of rheumatoid arthritis in clinical practice: contributions from clinical trials. Nat Clin Pract Rheumatol. 2006;2:611–8.CrossRefPubMed Zatarain E, Strand V. Monitoring disease activity of rheumatoid arthritis in clinical practice: contributions from clinical trials. Nat Clin Pract Rheumatol. 2006;2:611–8.CrossRefPubMed
37.
go back to reference Taal E, Rasker JJ, Seydel ER, Wiegman O. Health status, adherence with health recommendations, self-efficacy and social support in patients with rheumatoid arthritis. Patient Educ Couns. 1993;20:63–76.CrossRefPubMed Taal E, Rasker JJ, Seydel ER, Wiegman O. Health status, adherence with health recommendations, self-efficacy and social support in patients with rheumatoid arthritis. Patient Educ Couns. 1993;20:63–76.CrossRefPubMed
38.
go back to reference Leeb BF, Andel I, Sautner J, Nothnagl T, Rintelen B. The DAS28 in rheumatoid arthritis and fibromyalgia patients. Rheumatology. 2004;43:1504–7.CrossRefPubMed Leeb BF, Andel I, Sautner J, Nothnagl T, Rintelen B. The DAS28 in rheumatoid arthritis and fibromyalgia patients. Rheumatology. 2004;43:1504–7.CrossRefPubMed
39.
go back to reference Pincus T, Sokka T. Quantitative clinical assessment in busy rheumatology settings: the value of short patient questionnaires. J Rheumatol. 2008;35:1235–7.CrossRefPubMed Pincus T, Sokka T. Quantitative clinical assessment in busy rheumatology settings: the value of short patient questionnaires. J Rheumatol. 2008;35:1235–7.CrossRefPubMed
40.
go back to reference Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol. 1994;21:2286–91.PubMed Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol. 1994;21:2286–91.PubMed
Metadata
Title
Patient-centered psoriatic arthritis (PsA) activity assessment by Stockerau Activity Score for Psoriatic Arthritis (SASPA)
Authors
Burkhard F Leeb
Pia M Haindl
Hans-Peter Brezinschek
Harsono T H Mai
Christoph Deutsch
Bernhard Rintelen
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2015
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/s12891-015-0512-7

Other articles of this Issue 1/2015

BMC Musculoskeletal Disorders 1/2015 Go to the issue